Abstract
Atherogenic dyslipidemia is characterized by moderate to marked elevation of LDL-C levels, elevated levels of triglycerides and subnormal levels of HDL-C. It is further characterized by high apoB:apoA-I ratios. Current international recommendations for the treatment of dyslipidemia and prevention of coronary heart disease are primarily focused on reducing LDL-C levels in persons with, or at risk of, premature development of cardiovascular (CV) disease. In this regard, there is convincing evidence from prospective intervention trials that the statins are the drugs of choice for lowering LDL-C levels, and consequently, for reduction of morbid-mortality due to CV disease. This review is focused on recent findings relating to the role of HDL-C in CV medicine: the impact of low HDL-C levels as a major, independent risk factor for coronary heart disease events and, conversely, on the potential beneficial effects of supranormal HDL levels (>50% percentile). The effect of HDL-C on plaque formation is complex, sin...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
